New York State Common Retirement Fund boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 6.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,144,031 shares of the company’s stock after buying an additional 187,040 shares during the period. New York State Common Retirement Fund owned approximately 0.30% of Eli Lilly and worth $258,754,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the stock. Ronna Sue Cohen raised its position in Eli Lilly and by 0.4% during the second quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock valued at $203,000 after buying an additional 9 shares during the period. Accredited Investors Inc. raised its position in Eli Lilly and by 0.4% during the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after buying an additional 14 shares during the period. Northwest Quadrant Wealth Management LLC raised its position in Eli Lilly and by 0.5% during the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after buying an additional 19 shares during the period. Oakworth Capital Inc. raised its position in Eli Lilly and by 0.3% during the second quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after buying an additional 20 shares during the period. Finally, Sfmg LLC raised its position in Eli Lilly and by 0.5% during the second quarter. Sfmg LLC now owns 4,258 shares of the company’s stock valued at $350,000 after buying an additional 20 shares during the period. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts have commented on the company. UBS AG downgraded Eli Lilly and to a “hold” rating and set a $85.00 target price on the stock. in a research note on Wednesday, July 26th. BMO Capital Markets restated a “sell” rating and issued a $71.00 target price on shares of Eli Lilly and in a research note on Thursday, September 28th. Morgan Stanley set a $86.00 target price on Eli Lilly and and gave the company a “hold” rating in a research note on Friday, October 6th. Piper Jaffray Companies restated a “buy” rating and issued a $105.00 target price on shares of Eli Lilly and in a research note on Friday, October 13th. Finally, Berenberg Bank restated a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a research note on Friday, August 4th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the stock. Eli Lilly and currently has a consensus rating of “Hold” and a consensus target price of $89.76.

In related news, major shareholder Lilly Endowment Inc sold 190,000 shares of the business’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the completion of the transaction, the insider now owns 123,682,287 shares of the company’s stock, valued at approximately $10,207,499,146.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 770,000 shares of company stock valued at $64,669,850 in the last three months. 0.20% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “Eli Lilly and Company (LLY) Position Lifted by New York State Common Retirement Fund” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.watchlistnews.com/eli-lilly-and-company-lly-position-lifted-by-new-york-state-common-retirement-fund/1694986.html.

Eli Lilly and Company (NYSE:LLY) opened at $83.29 on Friday. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $89.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. The firm has a market capitalization of $92,480.98, a PE ratio of 20.53, a P/E/G ratio of 1.85 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same quarter in the previous year, the firm earned $0.88 EPS. The firm’s revenue was up 9.0% compared to the same quarter last year. analysts forecast that Eli Lilly and Company will post 4.22 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.50%. Eli Lilly and’s dividend payout ratio is presently 98.58%.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.